Income statement, balance sheet and cash flow statement for the last 10 fiscal years, taken from the XBRL data Kura Oncology, Inc. files with the SEC in its annual reports.
In USD millions, except per-share amounts. Outflows in the cash flow statement are negative.
Income statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Revenue
0
53.9
67.5
Research and development
26.4
46.8
47.8
60.4
84.7
92.8
115
170
251
Selling, general and administrative
50.6
77.1
120
General and administrative
9.65
16.1
19.7
31.5
46.5
47.1
50.6
77.1
Operating expenses
28.4
36.1
62.9
67.5
91.9
131
140
166
247
371
Operating income
-140
-166
-193
-304
Interest expense
0.58
0.89
0.97
0.58
0.58
0.41
0.23
1.55
1.62
1.51
Interest income
0.5
0.75
Other non-operating income
0.81
0.64
2.44
4.34
2.27
0.79
4.03
13.2
21.2
25.3
Pre-tax income
-136
-153
-172
-278
Income tax
0
0
0
0
0
0
0
0
2.02
0.3
Net income
-27.6
-35.4
-60.4
-63.1
-89.6
-130
-136
-153
-174
-279
EBITDA
-139
-165
-192
-303
EPS, basic
-1.47
-1.52
-1.72
-1.51
-1.69
-1.97
-2.03
-2.08
-2.02
-3.18
EPS, diluted
-1.47
-1.52
-1.72
-1.51
-1.69
-1.97
-2.03
-2.08
-2.02
-3.18
Shares, basic (weighted)
18.7
23.2
35.2
41.9
53.1
66.4
67
73.2
86.2
87.7
Shares, diluted (weighted)
18.7
23.2
35.2
41.9
53.1
66.4
67
73.2
86.2
87.7
Balance sheet
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Cash and equivalents
9.73
11.4
16.1
26.1
325
90.7
51.8
37.3
224
149
Short-term investments
81.7
163
211
308
427
386
387
503
518
Receivables
2.06
8.8
Inventory
0
0.41
Other current assets
0.73
1.28
1.99
2.71
3.97
4.33
8.44
8.52
15.4
32.2
Total current assets
68.8
94.6
181
240
637
522
446
432
745
709
Property, plant and equipment
0.04
0.01
0.04
2.02
2.67
2.54
1.86
1.68
7.86
Lease right-of-use assets
0.23
6.33
5.57
3.84
6.99
5.8
7.3
Other non-current assets
0.97
1.2
1.18
2.09
1.36
3.31
3.5
7.6
7.85
14.5
Total assets
69.8
95.9
182
242
647
534
456
449
760
738
Accounts payable
0.64
1.25
3.94
3.53
2.75
3.24
1.53
2.3
1.47
5.02
Accrued liabilities
1.91
2.35
3.44
3.69
7.02
17
10.3
13.2
17.5
22.4
Deferred revenue
24.3
49
Short-term debt
1.53
0.25
3
2.61
0
Total current liabilities
5.45
10
13.6
15.6
26
22.5
24.1
35.3
78.7
117
Long-term debt
7.32
5.57
7.5
7.25
4.25
9.16
9.33
6.92
9.71
Lease liabilities
5.64
4.61
2.55
6.36
5.19
9.47
Other non-current liabilities
0.17
0.39
0.28
0.38
0.4
0.38
0.27
0.71
1.8
3.17
Total liabilities
12.9
16
21.4
23.2
36.3
27.4
36
51.7
347
564
Total debt
7.32
7.1
7.5
7.5
7.25
9.16
9.33
9.52
9.7
Paid-in capital
111
169
311
431
913
941
997
1,120
1,308
1,347
Retained earnings
-53.9
-89.3
-150
-213
-303
-433
-569
-721
-895
-1,174
Other comprehensive income
-0.02
-0.05
-0.13
0.33
0.05
-1.79
-8.03
-1.27
0.76
1.02
Shareholders' equity
56.9
79.9
161
219
611
507
420
397
414
174
Total equity
56.9
79.9
161
219
611
507
420
397
414
174
Total liabilities and equity
69.8
95.9
182
242
647
534
456
449
760
738
Shares outstanding
19.3
29.4
38.1
45.4
66.2
66.6
68.3
74.4
78.2
87.9
Cash flow statement
FY2016
FY2017
FY2018
FY2019
FY2020
FY2021
FY2022
FY2023
FY2024
FY2025
Net income
-27.6
-35.4
-60.4
-63.1
-89.6
-130
-136
-153
-174
-279
Depreciation and amortization
0.03
0.03
0.01
0
0.19
0.56
0.76
0.85
0.85
1.03
Stock-based compensation
2.09
4.55
8.65
9.41
12.8
23.6
26.3
28.1
33.9
37.1
Change in receivables
0
-2.06
-6.74
Change in inventory
0
0
-0.41
Change in payables
3.05
5.12
0.86
5.68
-2.52
-0.8
-0.92
-1.63
4.5
Cash from operations
-25.3
-28.4
-48.7
-54.8
-69.8
-105
-110
-125
134
-64.1
Capital expenditures
-2.17
-1.15
-0.63
-0.17
-0.47
-6.64
Purchases of investments
-56.4
-101
-237
-228
-321
-446
-271
-410
-659
-762
Sales and maturities of investments
68.6
77.2
158
181
223
320
304
426
Cash from investing
12.2
-23.4
-79.3
-46.3
-99.9
-127
32.6
15.6
-102
-13.1
Debt issued
7.45
0.63
10
Debt repaid
-1.25
-0.25
-7.25
Stock issued
53.7
132
108
459
24.7
Cash from financing
7.45
53.6
133
111
469
-3.44
38.6
94.8
154
1.79
Net change in cash
-5.72
1.71
4.69
10
300
-235
-38.9
-14.5
187
-75.4
Free cash flow
-72
-106
-111
-125
134
-70.7
Interest paid
0.35
0.63
0.64
0.43
0.42
0.78
0.07
1.06
1.1
1
Income taxes paid
2.31
Key metrics
Worked out from the statements above. Latest values use the trailing twelve months to June 30, 2026; growth uses fiscal years. Valuation uses the share price of $10.76 on September 25, 2026.
Profitability
Metric
Value
How it is calculated
Operating margin
-411.9%
Operating income / revenue.
EBITDA margin
-410.2%
EBITDA (operating income + depreciation and amortization) / revenue.
Pre-tax margin
-384.2%
Pre-tax income / revenue.
Net margin
-384.3%
Net income / revenue.
FCF margin
-152.1%
Free cash flow (cash from operations - capital expenditures) / revenue.
Operating cash flow margin
-144.7%
Cash from operations / revenue.
Return on equity (ROE)
-612.8%
Net income / average shareholders' equity (opening and closing). Not shown when equity is negative.
Return on assets (ROA)
-50.5%
Net income / average total assets.
R&D / revenue
336.0%
Research and development expense / revenue.
Stock-based pay / revenue
50.4%
Stock-based compensation (from the cash flow statement) / revenue.
Capex / revenue
7.3%
Capital expenditures / revenue.
D&A / revenue
1.7%
Depreciation and amortization / revenue.
Growth
Metric
Value
How it is calculated
Revenue growth, 1y
25.2%
Revenue vs the same period a year earlier. Only from a positive base.
Operating cash flow growth, 1y
-147.7%
Operating cash flow vs the same period a year earlier. Only from a positive base.
Free cash flow growth, 1y
-152.8%
Free cash flow vs the same period a year earlier. Only from a positive base.
Book value growth, 1y
-57.9%
Book value vs the same period a year earlier. Only from a positive base.
Book value CAGR, 3y
-25.4%
Compound annual growth of book value over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Book value CAGR, 5y
-22.2%
Compound annual growth of book value over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Total assets growth, 1y
-2.9%
Total assets vs the same period a year earlier. Only from a positive base.
Total assets CAGR, 3y
17.4%
Compound annual growth of total assets over 3 fiscal years: (end / start)^(1/3) - 1. Only when both values are positive.
Total assets CAGR, 5y
2.7%
Compound annual growth of total assets over 5 fiscal years: (end / start)^(1/5) - 1. Only when both values are positive.
Share count change, 1y
1.8%
Change in diluted weighted shares vs a year earlier. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 3y
9.4%
Change in diluted weighted shares, per year over 3 years. Negative means buybacks shrank the share count; positive means dilution.
Share count change per year, 5y
10.6%
Change in diluted weighted shares, per year over 5 years. Negative means buybacks shrank the share count; positive means dilution.
Balance sheet health
Metric
Value
How it is calculated
Current ratio
4.73x
Current assets / current liabilities.
Quick ratio
4.47x
(Cash + short-term investments + receivables) / current liabilities.
Cash ratio
4.39x
(Cash + short-term investments) / current liabilities.
Debt / equity
0.20x
Total debt / shareholders' equity. Not shown when equity is negative.
Debt / assets
1.7%
Total debt / total assets.
Liabilities / assets
91.8%
Total liabilities / total assets.
Net debt
-$509.2M
Total debt - cash - short-term investments. Negative means more cash than debt.
Net income per diluted share, as reported (split-adjusted). Over the last twelve months: the four quarters summed, or net income / latest diluted shares when a quarter has no reported EPS.
Revenue per share
$0.87
Revenue / diluted weighted shares.
FCF per share
-$1.32
Free cash flow / diluted weighted shares.
Operating cash flow per share
-$1.26
Cash from operations / diluted weighted shares.
Book value per share
$0.54
Shareholders' equity / shares outstanding (diluted weighted shares when not reported).
Market cap + total debt - cash - short-term investments.
P/S
12.4x
Market cap / revenue.
P/B
19.8x
Market cap / shareholders' equity. Only when equity is positive.
Price / tangible book
19.8x
Market cap / tangible book value, when positive.
EV/Sales
5.80x
Enterprise value / revenue.
FCF yield
-12.3%
Free cash flow / market cap.
Earnings yield
-31.0%
Net income / market cap (the inverse of P/E).
What was Kura Oncology, Inc.'s revenue in fiscal 2025?
Kura Oncology, Inc. reported revenue of $67.5M for fiscal 2025, 25.2% higher than the year before.
Was Kura Oncology, Inc. profitable in fiscal 2025?
No. It reported a net loss of $278.7M.
How much free cash flow did Kura Oncology, Inc. generate in fiscal 2025?
Cash from operations of $64.1M minus capital expenditures of $6.6M left free cash flow of -$70.7M.
Source: SEC EDGAR XBRL company facts. Where a company tags only year-to-date figures, quarters are worked out as differences. Where a line is not tagged it is left empty, never estimated.